Treatment Services

Lutesyum-177 PSMA Therapy

Lutetium-177 PSMA therapy is an innovative and effective treatment that is increasingly used to treat metastatic castration-resistant prostate cancer. Generally, it is used with the recommendation of the follow-up doctor when other approved methods are exhausted, shown to be ineffective, or patients cannot tolerate them. This treatment; It helps to reduce tumor size and prevent tumor proliferation, as well as reduce the signs and symptoms caused by the tumor.

Click for detailed information.

Radium-223 Therapy

Radium-223 treatment is a type of treatment used in patients with prostate cancer that has metastasized (spread) to the bones, with the recommendation of the following physicians. Its purpose is to damage cancer cells in the bone, causing the tumors to shrink or even disappear completely. It is also used to reduce cancer-related pain in the bones.

Click for detailed information.

Lutetium-177 DOTA-TATE Therapy

Lutetium-177 DOTA-TATE; It is a treatment method used in neuroendocrine tumors. It is also known as “targeted radionuclide therapy”, “peptide receptor radionuclide therapy (PRRT)” “somatostatin receptor radioligand therapy.

Click for detailed information.

Radioactive Iodine Treatment

Radioactive iodine therapy is a standard practice that has been frequently preferred in the treatment of benign and malignant (cancer) diseases of the thyroid since the 1940’s and has been shown to have an effect on survival in patients with thyroid cancer. Specific and targeted treatment of tumoral tissues can be performed with high dose radioactive iodine 131I.

Click for detailed information.

Yttrium-90 Microsphere Therapy

With yttrium-90 (90Y) microsphere treatment, targeted treatment of tumoral tissues detected by 99mTc-MAA liver perfusion scintigraphy can be performed. It is a very successful and new method for theranostic applications.

Click for detailed information.

Why MNT is different?

We carried our experience and expertise in nuclear medicine and radiation oncology into the field of theranostics. We aim to provide cancer patients with access to theranostic diagnosis and treatment methods with an optimum quality-cost balance. In the world, we successfully implement all of the methods to JCI accredited health institutions

Click for detailed information.